# US 2024/0199758 A1 · Method for allowing immune cells infiltration in tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199758 A1
- Document ID: US20240199758A1
- Status: Published application
- Kind: A1
- Application number: 18/287,327
- Filed: 2021-04-27
- Published: 2024-06-20
- Earliest claimed: 2021-04-27
- Assignees: Alethia Biotherapeutics Inc.
- Applicants: Alethia Biotherapeutics Inc.
- Inventors: Mario FILION
- Web page: https://patentgrep.com/patent/US20240199758A1

## CPC

- C07K 16/30: from tumour cells
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure generally relates to a method for allowing intra-tumor immune infiltration and/or for treating a subject having cancer. The method of the present disclosure is based on the administration of an anti-clusterin antibody or antigen binding fragment thereof either as a single agent or in combination therapy with docetaxel. Combination therapy, medicament and kits for such use are also provided.

## Claims

### Claim 1

A method for allowing infiltration of immune cells in a tumor microenvironment, the method comprising administering to a subject in need thereof an anti-clusterin antibody or an antigen binding fragment thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method results in an increase of immune cells in the tumor microenvironment.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the anti-clusterin antibody or antigen binding fragment thereof is administered at a dose and/or an administration interval and/or for a treatment period sufficient to result in infiltration of immune cells in the tumor microenvironment.

### Claim 4

The method of any one of the preceding claims, wherein the method also comprises a step of administering docetaxel to the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein docetaxel is administered at a dose and/or an administration interval and/or for a treatment period sufficient to allow chemotherapy-induced immunogenic modulation of tumor.

### Claim 6

The method of any one of the preceding claims, wherein the method results in modulation of an immune response towards tumor cells.

### Claim 7

The method of any one of the preceding claims, wherein the subject has a functional immune system.

### Claim 8

A method of treating a subject having cancer, the method comprising administering a combination therapy comprising an anti-clusterin antibody or antigen binding fragment thereof and docetaxel, wherein the subject has a functional immune system.

### Claim 9 (depends on 4, 5, 6, 7, 8)

The method of any one of claims 4 to 8, wherein the anti-clusterin antibody or antigen binding fragment thereof and docetaxel are each administered at a dose and/or an administration interval and/or for a treatment period sufficient to allow infiltration of immune cells in a tumor microenvironment and/or chemotherapy-induced immunogenic modulation of tumor.

### Claim 10

The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO:9 and a heavy chain variable region comprising the CDRs of the heavy chain variable region set forth in SEQ ID NO:10.

### Claim 11

The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain variable region having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:9 and a heavy chain variable region having an amino acid sequence at least 80% identity with the amino acid sequence set forth in SEQ ID NO:10.

### Claim 12

The method of any of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:11 and a heavy chain having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:12.

### Claim 13

The method of any of the preceding claims, wherein the antibody or antigen binding fragment thereof is capable of competing with an antibody comprising a light chain variable region having an amino acid sequence set forth in SEQ ID NO:9 and a heavy chain variable region having an amino acid sequence set forth in SEQ ID NO:10 for the binding of clusterin.

### Claim 14

The method of any of the preceding claims, wherein the method results in infiltration of immune cells in a primary tumor microenvironment.

### Claim 15

The method of any one of the preceding claims, wherein the immune cells comprise plasmocytes.

### Claim 16

The method of any one of the preceding claims, wherein the immune cells comprise T cells.

### Claim 17 (depends on 16)

The method of claim 16, wherein the T cells comprise CD4+ T cells.

### Claim 18 (depends on 16)

The method of claim 16, wherein the T cells comprise CD8+ T cells.

### Claim 19

The method of any one of the preceding claims, wherein the immune cells comprise B cells.

### Claim 20

The method of any of the preceding claims, wherein the treatment results in necrosis of a tumor.

### Claim 21

The method of any one of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof is administered once weekly.

### Claim 22

The method of any one of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof is administered twice weekly.

### Claim 23

The method of any one of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof is administered once every two weeks.

### Claim 24

The method of any one of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof is administered once every three weeks.

### Claim 25

The method of any one of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof is administered once every four weeks.

### Claim 26 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 4 to 25, wherein docetaxel is administered once every week.

### Claim 27 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 4 to 25, wherein docetaxel is administered once every two weeks.

### Claim 28 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 4 to 25, wherein docetaxel is administered once every three weeks.

### Claim 29 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 4 to 25, wherein docetaxel is administered once every four weeks.

### Claim 30

The method of any one of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof is administered at a dose of between approximately 3 mg/kg to approximately 20 mg/kg.

### Claim 31

The method of any one of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof is administered at a dose of approximately 6 mg/kg.

### Claim 32

The method of any one of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof is administered at a dose of approximately 9 mg/kg.

### Claim 33

The method of any one of the preceding claims, wherein the anti-clusterin antibody or antigen binding fragment thereof is administered at a dose of approximately 12 mg/kg.

### Claim 34 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 4 to 33, wherein docetaxel is administered at a dose of between approximately 60 mg/m2 to approximately 100 mg/m2.

### Claim 35 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 4 to 34, wherein docetaxel is administered at a dose of approximately 60 mg/m2.

### Claim 36 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 4 to 34, wherein docetaxel is administered at a dose of approximately 75 mg/m2.

### Claim 37 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 34, 36)

The method of any one of claims 4 to 30, 33, 34 or 36, wherein the subject is treated with the anti-clusterin antibody or antigen binding fragment thereof at a dose of approximately 12 mg/kg once weekly and docetaxel at a dose of approximately 75 mg/m2 once every three weeks.

### Claim 38 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35)

The method of any one of claims 4 to 30, 33, 34 or 35, wherein the subject is treated with the anti-clusterin antibody or antigen binding fragment thereof at a dose of approximately 12 mg/kg once weekly and docetaxel at a dose of approximately 60 mg/m2 once every three weeks.

### Claim 39 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36)

The method of any one of claims 4 to 30, 32, 34 or 36, wherein the subject is treated with the anti-clusterin antibody or antigen binding fragment thereof at a dose of approximately 9 mg/kg once weekly and docetaxel at a dose of approximately 75 mg/m2 once every three weeks.

### Claim 40 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 35)

The method of any one of claims 4 to 30, 32, 34 or 35, wherein the subject is treated with the anti-clusterin antibody or antigen binding fragment thereof at a dose of approximately 9 mg/kg once weekly and docetaxel at a dose of approximately 60 mg/m2 once every three weeks.

### Claim 41 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 34, 36)

The method of any one of claims 4 to 30, 31, 34 or 36, wherein the subject is treated with the anti-clusterin antibody or antigen binding fragment thereof at a dose of approximately 6 mg/kg once weekly and docetaxel at a dose of approximately 75 mg/m2 once every three weeks.

### Claim 42 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 34, 35)

The method of any one of claims 4 to 30, 31,34 or 35, wherein the subject is treated with the anti-clusterin antibody or antigen binding fragment thereof at a dose of approximately 6 mg/kg once weekly and docetaxel at a dose of approximately 60 mg/m2 once every three weeks.

### Claim 43 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 34, 36)

The method of any one of claims 4 to 30, 34 or 36, wherein the subject is treated with the anti-clusterin antibody or antigen binding fragment thereof at a dose of approximately 3 mg/kg once weekly and docetaxel at a dose of approximately 75 mg/m2 once every three weeks.

### Claim 44 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 34, 35)

The method of any one of claims 4 to 30, 34 or 35, wherein the subject is treated with the anti-clusterin antibody or antigen binding fragment thereof at a dose of approximately 3 mg/kg once weekly and docetaxel at a dose of approximately 60 mg/m2 once every three weeks.

### Claim 45 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 4 to 44, wherein the anti-clusterin antibody or antigen binding fragment thereof and docetaxel are administered on same day.

### Claim 46 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 4 to 45, wherein the anti-clusterin antibody or antigen binding fragment thereof and/or docetaxel is administered by infusion over approximately a 1-hour time frame.

### Claim 47 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 4 to 46, wherein the anti-clusterin antibody or antigen binding fragment thereof and docetaxel are essentially both administered essentially over the entire course of the treatment period.

### Claim 48

The method of any one of the preceding claims, wherein the subject has a carcinoma.

### Claim 49

The method of any one of the preceding claims, wherein the carcinoma is metastatic.

### Claim 50

The method of any of the preceding claims wherein the subject in need has or is selected for having a tumor characterized as immunologically cold.

### Claim 51

The method of any of the preceding claims wherein the subject in need has or is selected for having a tumor characterized as immunologically warm or hot that is non-responsive to immunotherapy.

### Claim 52

The method of any one of the preceding claims, wherein the subject has or is selected for having a carcinoma that progressed after a first line immune checkpoint therapy.

### Claim 53

The method of any one of the preceding claims, wherein the subject has or is selected for having a carcinoma that has failed prior treatment with a platinum-containing doublet treatment and immune checkpoint therapy.

### Claim 54

The method of any one of the preceding claims, wherein the subject has or is selected for having a carcinoma that has failed prior treatment with a platinum-containing doublet treatment and an anti-PD1 or PDL-1 immune checkpoint antibody.

### Claim 55

The method of any one of the preceding claims, wherein the subject in need has an endometrial cancer, a breast cancer, a liver cancer, a prostate cancer, a renal cancer, an ovarian cancer, a colorectal cancer, a pancreatic cancer, a lung cancer, a gastric cancer, a head and neck cancer, a thyroid cancer, a cholangiocarcinoma, a mesothelioma or a melanoma.

### Claim 56

The method of any one of the preceding claims, wherein the subject in need has a metastatic endometrial cancer, a metastatic breast cancer, a metastatic liver cancer, a metastatic prostate cancer, a metastatic renal cancer, a metastatic ovarian cancer, a metastatic colorectal cancer, a metastatic pancreatic cancer, a metastatic lung cancer, a metastatic gastric cancer, a metastatic head and neck cancer, a metastatic thyroid cancer, a metastatic cholangiocarcinoma, a metastatic mesothelioma or a metastatic melanoma.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1 to 54, wherein the subject has non-small cell lung cancer (NSCLC).

### Claim 58 (depends on 57)

The method of claim 57, wherein NSCLC is metastatic NSCLC.

### Claim 59 (depends on 57)

The method of claim 57, wherein NSCLC is stage III to IV NSCLC.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1 to 54, wherein the subject has breast cancer.

### Claim 61 (depends on 60)

The method of claim 60, wherein the breast cancer is metastatic breast cancer.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1 to 54, wherein the subject has prostate cancer.

### Claim 63 (depends on 62)

The method of claim 62, wherein the prostate cancer is metastatic prostate cancer.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1 to 54, wherein the subject has gastric cancer.

### Claim 65 (depends on 64)

The method of claim 64, wherein the gastric cancer is metastatic.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1 to 54, wherein the subject has head and neck cancer.

### Claim 67 (depends on 66)

The method of claim 66, wherein the head and neck cancer is metastatic.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1 to 54, wherein the subject has thyroid cancer.

### Claim 69 (depends on 68)

The method of claim 68, wherein the thyroid cancer is metastatic.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1 to 54, wherein the subject has ovarian cancer.

### Claim 71 (depends on 70)

The method of claim 70, wherein the ovarian cancer is metastatic.

### Claim 72

The method of any one of the preceding claims, wherein the subject is not immunosuppressed or has not received an immunosuppressive medication within 7 days prior to treatment.

### Claim 73

The method of any one of the preceding claims, wherein the subject has not received prior treatment with docetaxel.

### Claim 74

The method of any of the preceding claims, wherein the subject is treated for at least two cycles of treatment.

### Claim 75

The method of any of the preceding claims, wherein infiltration of immune cells in a tumor microenvironment is confirmed by biopsy.

### Claim 76

The method of any of the preceding claims, wherein infiltration of immune cells in a tumor microenvironment is confirmed by imaging.

### Claim 77

The method of any of the preceding claims, wherein the treatment results in the tumor being more susceptible to treatment by immunotherapy.

### Claim 78

The method of any one of the preceding claims, wherein the treatment comprises administering immunotherapy after one or more cycle of combination therapy.

### Claim 79 (depends on 77, 78)

The method of claim 77 or 78, wherein the wherein the immunotherapy comprises cellular immunotherapy.

### Claim 80 (depends on 77, 78)

The method of claim 77 or 78, wherein the wherein the immunotherapy comprises an immune checkpoint inhibitor.

### Claim 81

The method of any one of the preceding claims, wherein the subject does not receive concurrent anti-cancer treatment with than the anti-clusterin antibody or antigen binding fragment thereof and/or docetaxel combination treatment.

### Claim 82

The method of any one of the preceding claims, wherein the subject is a human subject.

### Claim 83

A combination therapy comprising a pharmaceutical composition comprising an anti-clusterin antibody or antigen binding fragment thereof formulated for administration at a dose of between approximately 3 mg/kg to approximately 20 mg/kg and a pharmaceutical composition comprising docetaxel formulated for administration at a dose of approximately 60 mg/m2 to 100 mg/m2.

### Claim 84 (depends on 83)

The combination therapy of claim 83, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO:9 and a heavy chain variable region comprising the CDRs of the heavy chain variable region set forth in SEQ ID NO:10.

### Claim 85 (depends on 83, 84)

The combination therapy of claim 83 or 84, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain variable region having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:9 and a heavy chain variable region having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:10.

### Claim 86 (depends on 83, 84)

The combination therapy of claim 83 or 84, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:11 and a heavy chain having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:12.

### Claim 87 (depends on 83, 84, 85, 86)

The combination therapy of any one of claims 83 to 86, wherein the antibody or antigen binding fragment thereof is capable of competing with an antibody comprising a light chain variable region having an amino acid sequence set forth in SEQ ID NO:9 and a heavy chain variable region having an amino acid sequence set forth in SEQ ID NO: 10 for the binding of clusterin.

### Claim 88 (depends on 83, 84, 85, 86, 87)

The combination therapy of any one of claims 83 to 87, wherein the combination therapy is used for allowing infiltration of immune cells in a tumor microenvironment in a subject in need thereof.

### Claim 89 (depends on 83, 84, 85, 86, 87, 88)

The combination therapy of any one of claims 83 to 88, wherein the combination therapy is used for treating a subject having cancer.

### Claim 90 (depends on 89)

The combination therapy of claim 89, wherein the cancer is a carcinoma.

### Claim 91 (depends on 90)

The combination therapy of claim 90, wherein the carcinoma is metastatic.

### Claim 92 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91)

The combination therapy of any one of claims 83 to 91, wherein the subject in need has or is selected for having a tumor characterized as immunologically cold.

### Claim 93 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The combination therapy of any one of claims 83 to 92, wherein the subject in need has or is selected for having a tumor characterized as immunologically warm or hot that is non-responsive to immunotherapy.

### Claim 94 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The combination therapy of any one of claims 83 to 93, wherein the combination therapy is used for treating a subject having or selected for having a carcinoma that progressed after a first line immune checkpoint therapy.

### Claim 95 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The combination therapy of any one of claims 83 to 94, wherein the combination therapy is used for treating a subject having or selected for having a carcinoma that has failed prior treatment with a platinum-containing doublet treatment and immune checkpoint therapy.

### Claim 96 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The combination therapy of any one of claims 83 to 95, wherein the combination therapy is used for treating a subject having or selected for having a carcinoma that has failed prior treatment with a platinum-containing doublet treatment and an anti-PD1 or PDL-1 immune checkpoint antibody.

### Claim 97 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The combination therapy of any one of claims 83 to 96, wherein the combination therapy is used for treating a subject having an endometrial cancer, a breast cancer, a liver cancer, a prostate cancer, a renal cancer, an ovarian cancer, a colorectal cancer, a pancreatic cancer, a lung cancer, a gastric cancer, a head and neck cancer, a thyroid cancer, a cholangiocarcinoma, a mesothelioma or a melanoma.

### Claim 98 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The combination therapy of any one of claims 83 to 96, wherein the combination therapy is used for treating a subject having a metastatic endometrial cancer, a metastatic breast cancer, a metastatic liver cancer, a metastatic prostate cancer, a metastatic renal cancer, a metastatic ovarian cancer, a metastatic colorectal cancer, a metastatic pancreatic cancer, a metastatic lung cancer, a metastatic gastric cancer, a metastatic head and neck cancer, a metastatic thyroid cancer, a metastatic cholangiocarcinoma, a metastatic mesothelioma or a metastatic melanoma.

### Claim 99 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The combination therapy of any one of claims 83 to 96, wherein the combination therapy is used for treating a subject having non-small cell lung cancer (NSCLC).

### Claim 100 (depends on 99)

The combination therapy of claim 99, wherein NSCLC is metastatic NSCLC.

### Claim 101 (depends on 99)

The combination therapy of claim 99, wherein NSCLC is stage III to IV NSCLC.

### Claim 102 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The combination therapy of any one of claims of claims 83 to 98, wherein the combination therapy is used for treating a subject having breast cancer.

### Claim 103 (depends on 102)

The combination therapy of claim 102, wherein the breast cancer is metastatic breast cancer.

### Claim 104 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The combination therapy of any one of claims of claims 83 to 98, wherein the combination therapy is used for treating a subject having prostate cancer.

### Claim 105 (depends on 104)

The combination therapy of claim 104, wherein the prostate cancer is metastatic prostate cancer.

### Claim 106 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The combination therapy of any one of claims of claims 83 to 98, wherein the combination therapy is used for treating a subject having gastric cancer.

### Claim 107 (depends on 106)

The combination therapy of claim 106, wherein the gastric cancer is metastatic.

### Claim 108 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The combination therapy of any one of claims of claims 83 to 98, wherein the combination therapy is used for treating a subject having head and neck cancer.

### Claim 109 (depends on 108)

The combination therapy of claim 108, wherein the head and neck cancer is metastatic.

### Claim 110 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The combination therapy of any one of claims of claims 83 to 98, wherein the combination therapy is used for treating a subject having thyroid cancer.

### Claim 111 (depends on 110)

The combination therapy of claim 110, wherein the thyroid cancer is metastatic.

### Claim 112 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The combination therapy of any one of claims of claims 83 to 98, wherein the combination therapy is used for treating a subject having ovarian cancer.

### Claim 113 (depends on 112)

The combination therapy of claim 112, wherein the ovarian cancer is metastatic.

### Claim 114 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)

The combination therapy of any one of claims 83 to 113, wherein the combination therapy is for use in a subject that is not immunosuppressed or that has not received an immunosuppressive medication within 7 days prior to treatment.

### Claim 115 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The combination therapy of any one of claims 83 to 114, wherein the combination therapy is for use in a subject that has not received prior treatment with docetaxel.

### Claim 116 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The combination therapy of any one of claims 83 to 115, wherein the pharmaceutical composition comprising the anti-clusterin antibody or antigen binding fragment thereof and the pharmaceutical composition comprising docetaxel are both administered essentially over the entire course of the treatment period.

### Claim 117 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The combination therapy of any one of claims 83 to 116, wherein the subject is a human subject.

### Claim 118 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117)

The combination therapy of any one of claims 83 to 117, wherein the subject has a functional immune system.

### Claim 119 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The combination therapy any one of claims 83 to 118, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 6 mg/kg.

### Claim 120 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The combination therapy any one of claims 83 to 118, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 9 mg/kg.

### Claim 121 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The combination therapy any one of claims 83 to 118, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 12 mg/kg.

### Claim 122 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The combination therapy of any one of claims 83 to 121, wherein docetaxel is used at a dose of approximately 60 mg/m2.

### Claim 123 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The combination therapy of any one of claims 83 to 121, wherein docetaxel is used at a dose of approximately 75 mg/m2.

### Claim 124 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 121, 123)

The combination therapy of any one of claims 83 to 118, 121 or 123, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 12 mg/kg once weekly and docetaxel is used at a dose of approximately 75 mg/m2 once every three weeks.

### Claim 125 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 121, 122)

The combination therapy of any one of claims 83 to 118 or 121 or 122, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 12 mg/kg once weekly and docetaxel is used at a dose of approximately 60 mg/m2 once every three weeks.

### Claim 126 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 120, 123)

The combination therapy of any one of claims 83 to 118, 120 or 123, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 9 mg/kg once weekly and docetaxel is used at a dose of approximately 75 mg/m2 once every three weeks.

### Claim 127 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 120, 122)

The combination therapy of any one of claims 83 to 118, 120 or 122, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 9 mg/kg once weekly and docetaxel is used at a dose of approximately 60 mg/m2 once every three weeks.

### Claim 128 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 123)

The combination therapy of any one of claims 83 to 118, 119 or 123, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 6 mg/kg once weekly and docetaxel is used at a dose of approximately 75 mg/m2 once every three weeks.

### Claim 129 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 122)

The combination therapy of any one of claims 83 to 118, 119 or 122, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 6 mg/kg once weekly and docetaxel is used at a dose of approximately 60 mg/m2 once every three weeks.

### Claim 130 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 122, 123)

The combination therapy of any one of claims 83 to 118, 122 or 123, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 3 mg/kg once weekly and docetaxel is used at a dose of approximately 75 mg/m2 once every three weeks.

### Claim 131 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 122, 123)

The combination therapy of any one of claims 83 to 118, 122 or 123, wherein the anti-clusterin antibody or antigen binding fragment thereof is used at a dose of approximately 3 mg/kg once weekly and docetaxel is used at a dose of approximately 60 mg/m2 once every three weeks.

### Claim 132

A kit comprising one or more containers comprising at least one dose of an anti-clusterin antibody or antigen binding fragment thereof, one or more containers comprising at least one dose of docetaxel for use in combination therapy and a package insert comprising instructions for treating a subject in need.

### Claim 133 (depends on 132)

The kit of claim 132, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO:9 and a heavy chain variable region comprising the CDRs of the heavy chain variable region set forth in SEQ ID NO:10.

### Claim 134 (depends on 132, 133)

The kit of claim 132 or 133, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain variable region having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:9 and a heavy chain variable region having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:10.

### Claim 135 (depends on 132, 133)

The kit of claim 132 or 133, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain having an amino acid sequence having at least 80% identity with the amino acid sequence set forth set forth in SEQ ID NO:11 and a heavy chain having an amino acid sequence having at least 80% identity with the amino acid sequence set forth set forth in SEQ ID NO:12.

### Claim 136 (depends on 132, 133, 134, 135)

The kit of any one of claims 132 to 135, wherein the antibody or antigen binding fragment thereof is capable of competing with an antibody comprising a light chain variable region having an amino acid sequence set forth in SEQ ID NO:9 and a heavy chain variable region having an amino acid sequence set forth in SEQ ID NO:10 for the binding of clusterin.

### Claim 137 (depends on 132, 133, 134, 135, 136)

The kit of any one of claims 132 to 136, wherein the package insert states that the combination therapy is intended for treatment of a subject having a carcinoma.

### Claim 138 (depends on 137)

The kit of claim 137, wherein the carcinoma is metastatic.

### Claim 139 (depends on 132, 133, 134, 135, 136, 137, 138)

The kit of any one of claims 132 to 138, wherein the subject in need has or is selected for having a tumor characterized as immunologically cold.

### Claim 140 (depends on 132, 133, 134, 135, 136, 137, 138, 139)

The kit of any one of claims 132 to 139, wherein the subject in need has or is selected for having a tumor characterized as immunologically warm or hot that is non-responsive to immunotherapy.

### Claim 141 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140)

The kit of any one of claims 132 to 140, wherein the package insert states that the combination therapy is intended for treatment of a subject having a carcinoma that progressed after a first line immune checkpoint therapy.

### Claim 142 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141)

The kit of any one of claims 132 to 141, wherein the package insert states that the combination therapy is intended for treatment of a subject having a carcinoma that has failed prior treatment with a platinum-containing doublet treatment and immune checkpoint therapy.

### Claim 143 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142)

The kit of any one of claims 132 to 142, wherein the package insert states that the combination therapy is intended for treatment of a subject having a carcinoma that has failed prior treatment with a platinum-containing doublet treatment and an anti-PD1 or PDL-1 immune checkpoint antibody.

### Claim 144 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The kit of any one of claims 132 to 143, wherein the package insert states that the combination therapy is intended for treatment of a subject having cancer and wherein the cancer is selected from endometrial cancer, breast cancer, liver cancer, prostate cancer, renal cancer, ovarian cancer, colorectal cancer, pancreatic cancer, lung cancer, gastric cancer, head and neck cancer, thyroid cancer,
cholangiocarcinoma, mesothelioma or melanoma.

### Claim 145 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The kit of any one of claims 132 to 143, wherein the package insert states that the combination therapy is intended for treatment of a subject having cancer and wherein the cancer is selected from metastatic endometrial cancer, a metastatic breast cancer, metastatic liver cancer, metastatic prostate cancer, metastatic renal cancer, metastatic ovarian cancer, metastatic colorectal cancer, metastatic pancreatic cancer, metastatic lung cancer, metastatic gastric cancer, metastatic head and neck cancer, metastatic thyroid cancer, metastatic cholangiocarcinoma, metastatic mesothelioma or a metastatic melanoma.

### Claim 146 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The kit of any one of claims 132 to 143, wherein the package insert states that the combination therapy is intended for treatment of a subject having non-small cell lung cancer (NSCLC).

### Claim 147 (depends on 146)

The kit of claim 146, wherein NSCLC is advanced NSCLC.

### Claim 148 (depends on 146)

The kit of claim 146, wherein NSCLC is stage III to IV NSCLC.

### Claim 149 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The kit of any one of claims 132 to 143, wherein the package insert states that the combination therapy is intended for treatment of a subject having breast cancer.

### Claim 150 (depends on 149)

The kit of claim 149, wherein the breast cancer is metastatic breast cancer.

### Claim 151 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The kit of any one of claims 132 to 143, wherein the package insert states that the combination therapy is intended for treatment of a subject having prostate cancer.

### Claim 152 (depends on 151)

The kit of claim 151, wherein the prostate cancer is metastatic prostate cancer.

### Claim 153 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The kit of any one of claims 132 to 143, wherein the package insert states that the combination therapy is intended for treatment of a subject having gastric cancer.

### Claim 154 (depends on 153)

The kit of claim 153, wherein the gastric cancer is metastatic.

### Claim 155 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The kit of any one of claims 132 to 143, wherein the package insert states that the combination therapy is intended for treatment of a subject having head and neck cancer.

### Claim 156 (depends on 155)

The kit of claim 155, wherein the head and neck cancer is metastatic.

### Claim 157 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The kit of any one of claims 132 to 143, wherein the package insert states that the combination therapy is intended for treatment of a subject having thyroid cancer.

### Claim 158 (depends on 157)

The kit of claim 157, wherein the thyroid is metastatic.

### Claim 159 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The kit of any one of claims 132 to 143, wherein the package insert states that the combination therapy is intended for treatment of a subject having ovarian cancer.

### Claim 160 (depends on 159)

The kit of claim 159, wherein the ovarian is metastatic.

### Claim 161 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The kit of any one of claims 132 to 143, wherein the package insert states that the combination therapy is intended for treatment of a subject that is not immunosuppressed has not received an immunosuppressive medication within 7 days prior to treatment.

### Claim 162 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161)

The kit of any one of claims 132 to 161, wherein the package insert states that the combination therapy is intended for treatment of a subject that has not received prior treatment with docetaxel.

### Claim 163 (depends on 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162)

The kit of any one of claims 132 to 162, wherein the package insert states that the combination therapy is for administration essentially over the entire course of the treatment period.

### Claim 164

A medicament comprising an anti-clusterin antibody or antigen binding fragment thereof for allowing infiltration of immune cells in a tumor microenvironment in a subject having cancer.

### Claim 165 (depends on 164)

The medicament of claim 164, wherein the medicament is for use in combination with docetaxel.

### Claim 166 (depends on 164, 165)

The medicament of claim 164 or 165, wherein the subject has a functional immune system.

### Claim 167

A medicament comprising an anti-clusterin antibody or antigen binding fragment thereof for use in combination with docetaxel for the treatment of a subject having cancer wherein the subject has a functional immune system.

### Claim 168 (depends on 164, 165, 166, 167)

The medicament of any one of claims 164 to 167, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain variable region comprising the complementarity determining regions (CDRs) of the light chain variable region set forth in SEQ ID NO:9 and a heavy chain variable region comprising the CDRs of the heavy chain variable region set forth in SEQ ID NO:10.

### Claim 169 (depends on 164, 165, 166, 167, 168)

The medicament of any one of claims 164 to 168, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain variable region having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:9 and a heavy chain variable region having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:10.

### Claim 170 (depends on 164, 165, 166, 167, 168)

The medicament of any one of claims 164 to 168, wherein the anti-clusterin antibody or antigen binding fragment thereof comprises a light chain having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:11 and a heavy chain having an amino acid sequence having at least 80% identity with the amino acid sequence set forth in SEQ ID NO:12.

### Claim 171 (depends on 164, 165, 166, 167, 168, 169, 170)

The medicament of any one of claims 164 to 170, wherein the antibody or antigen binding fragment thereof is capable of competing with an antibody comprising a light chain variable region having an amino acid sequence set forth in SEQ ID NO:9 and a heavy chain variable region having an amino acid sequence set forth in SEQ ID NO:10 for the binding of clusterin.

### Claim 172 (depends on 164, 165, 166, 167, 168, 169, 170, 171)

The medicament of any one of claims 164 to 171, wherein the anti-clusterin antibody or antigen binding fragment thereof is formulated as an injectable solution at a concentration of approximately 10 mg/mL.

### Claim 173 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172)

The medicament of any one of claims 164 to 172, wherein the anti-clusterin antibody or antigen binding fragment thereof is formulated as an intravenous infusion for delivery of a dose of between approximately 3 mg/kg to approximately 20 mg/kg.

### Claim 174 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The medicament of any one of claims 164 to 173, wherein docetaxel is formulated as an injectable solution at a concentration of between approximately 10 mg/mL to approximately 40 mg/mL.

### Claim 175 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174)

The medicament of any one of claims 164 to 174, wherein docetaxel is formulated is formulated as an intravenous infusion for delivery of a dose of between approximately 60 mg/m2 to approximately 100 mg/m2.

### Claim 176 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175)

The medicament of any one of claims 164 to 175, wherein the subject has a carcinoma.

### Claim 177 (depends on 176)

The medicament of claim 176, wherein the carcinoma is metastatic.

### Claim 178 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177)

The medicament of any one of claims 164 to 177, wherein the subject in need has or is selected for having a tumor characterized as immunologically cold.

### Claim 179 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178)

The medicament of any one of claims 164 to 178, wherein the subject in need has or is selected for having a tumor characterized as immunologically warm or hot that is non-responsive to immunotherapy.

### Claim 180 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179)

The medicament of any one of claims 164 to 179, wherein the subject has a carcinoma that progressed after a first line immune checkpoint therapy.

### Claim 181 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180)

The medicament of any one of claims 164 to 180, wherein the subject has a carcinoma that has failed prior treatment with a platinum-containing doublet treatment and immune checkpoint therapy.

### Claim 182 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181)

The medicament of any one of claims 164 to 181, wherein the subject has a carcinoma that has failed prior treatment with a platinum-containing doublet treatment and an anti-PD1 or PDL-1 immune checkpoint antibody.

### Claim 183 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The medicament of any one of claims 164 to 182, wherein the subject has an endometrial cancer, a breast cancer, a liver cancer, a prostate cancer, a renal cancer, an ovarian cancer, a colorectal cancer, a pancreatic cancer, a lung cancer, a gastric cancer, a head and neck cancer, a thyroid cancer, a cholangiocarcinoma, a mesothelioma or a melanoma.

### Claim 184 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The medicament of any one of claims 164 to 182, wherein the subject has a metastatic endometrial cancer, a metastatic breast cancer, a metastatic liver cancer, a metastatic prostate cancer, a metastatic renal cancer, a metastatic ovarian cancer, a metastatic colorectal cancer, a metastatic pancreatic cancer, a metastatic lung cancer, a metastatic gastric cancer, a metastatic head and neck cancer, a metastatic thyroid cancer, a metastatic cholangiocarcinoma, a metastatic mesothelioma or a metastatic melanoma.

### Claim 185 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The medicament of any one of claims 164 to 182, wherein the subject has non-small cell lung cancer (NSCLC).

### Claim 186 (depends on 185)

The medicament of claim 185, wherein NSCLC is advanced NSCLC.

### Claim 187 (depends on 185)

The medicament of claim 185, wherein NSCLC is stage III to IV NSCLC.

### Claim 188 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The medicament of any one of claims 164 to 182, wherein the subject has breast cancer.

### Claim 189 (depends on 188)

The medicament of claim 188, wherein the breast cancer is metastatic breast cancer.

### Claim 190 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The medicament of any one of claims 164 to 182, wherein the subject has prostate cancer.

### Claim 191 (depends on 190)

The medicament of claim 190, wherein the prostate cancer is metastatic prostate cancer.

### Claim 192 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The medicament of any one of claims 164 to 182, wherein the subject has gastric cancer.

### Claim 193 (depends on 192)

The medicament of claim 192, wherein the gastric cancer is metastatic.

### Claim 194 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The medicament of any one of claims 164 to 182, wherein the subject has head and neck cancer.

### Claim 195 (depends on 194)

The medicament of claim 194, wherein the head and neck cancer is metastatic.

### Claim 196 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The medicament of any one of claims 164 to 182, wherein the subject has thyroid cancer.

### Claim 197 (depends on 196)

The medicament of claim 196, wherein the thyroid is metastatic.

### Claim 198 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The medicament of any one of claims 164 to 182, wherein the subject has ovarian cancer.

### Claim 199 (depends on 198)

The medicament of claim 198, wherein the ovarian is metastatic.

### Claim 200 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199)

The medicament of any one of claims 164 to 199, wherein the subject is not immunosuppressed or has not received an immunosuppressive medication within 7 days prior to treatment.

### Claim 201 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200)

The medicament of any one of claims 164 to 200, wherein the subject that has not received prior treatment with docetaxel.

### Claim 202 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201)

The medicament of any one of claims 164 to 201, wherein each of the anti-clusterin antibody or antigen binding fragment and docetaxel are administered essentially over the entire course of the treatment period.

### Claim 203 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202)

A kit comprising one or more containers comprising at least one dose of the medicament of any one of claims 164 to 202 or the combination therapy of any one of any one of claims 83 to 131 and a package insert comprising instructions for treating a subject in need, wherein the anti-clusterin antibody or antigen binding fragment thereof and docetaxel are provided in separate containers.

### Claim 204

Use of an anti-clusterin antibody or an antigen binding fragment thereof for allowing infiltration of immune cells in a tumor microenvironment in a subject in need thereof.

### Claim 205

Use of an anti-clusterin antibody or an antigen binding fragment thereof in the manufacture of a medicament or kit for allowing infiltration of immune cells in a tumor microenvironment in a subject in need thereof.

### Claim 206 (depends on 204, 205)

The use as defined in claim 204 or 205, wherein the anti-clusterin antibody or an antigen binding fragment thereof is used in combination with docetaxel.

### Claim 207 (depends on 204, 205, 206)

The use as defined in any one of claims 204 to 206, wherein the subject has a functional immune system.

### Claim 208

Use of a combination therapy comprising an anti-clusterin antibody or antigen binding fragment thereof and docetaxel in the treatment of a subject having cancer, wherein the subject has a functional immune system.

### Claim 209

Use of an anti-clusterin antibody or antigen binding fragment thereof and docetaxel in the manufacture of a medicament or kit for the treatment of a subject having cancer, wherein the subject has a functional immune system.
